Amit Akirov, MD

Researchers examined whether treatment with CD20 inhibitors resulted in worse COVID-19 outcomes among patients with immune-mediated diseases.

Researchers assessed the humoral and cell-mediated immune responses to SARS-CoV-2 mRNA-based vaccines in patients with a history of receiving CD20-targeted B-cell-depleting therapy.

Researchers analyzed the autopsies of patients who died from COVID-19 to understand the pathophysiology of COVID-19-related myopathy.

Authors of a commentary assessed the role of IL-1 receptor antagonism, specifically anakinra, in the treatment of patients with severe COVID-19.

The American Academy of Sleep Medicine provided a position statement on the importance of sleep in health and several objectives to improve health, productivity, and well-being.

Researchers strove to provide robust estimates of incidence rates and relative risks of neurologic and psychiatric diagnoses in patients in the 6 months following a COVID-19 diagnosis.

This literature review explored the nature of racial bias in the clinical setting

In correspondence published in The Lancet Neurology, researchers proposed a new definition of adult brain health.

The immunogenicity and safety of SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions receiving immunosuppressive therapy were determined.

Researchers evaluated the contribution of abnormal GI transit to systemic sclerosis Medsger GI severity scores and/or UCLA GIT 2.0 symptoms.

Study authors evaluated the prevalence of axial spondyloarthritis in patients with inflammatory bowel disease in secondary care.

Researchers described the gastrointestinal manifestations of systemic erythematosus lupus and determined its association with disease activity, damage accrual, and prognosis.

Researchers evaluated the prevalence of serologic immunity against hepatitis B virus in immunocompromised patients with pediatric-onset inflammatory bowel disease and rheumatologic diseases.

Revisional bariatric surgery in patients with persistent metabolic disease may improve obesity-related comorbidities and metabolic outcomes.

Treatment with lixisenatide can significantly slow gastric emptying and reduce the rate of systemic appearance of orally ingested glucose.

Increased blood glucose levels, even within the nondiabetic range, are associated with increased risk for nonalcoholic fatty liver disease.

In patients with a known diagnosis of cirrhosis, hepatic exacerbations may increase the risk for hospitalization for epilepsy and status epilepticus.

With the use of age-adjusted thresholds for noninvasive markers of liver steatosis and fibrosis, patients with type 2 diabetes may be referred more efficiently to specialists.

Obesity was found to be associated with elevated markers of liver damage in children and adolescents.

In patients who underwent Roux-en-Y gastric bypass, bone material strength index was improved 1 year after surgery despite an increase in bone turnover and lower overall areal bone mineral density.

Hepatic-directed vesicle insulin, a novel liver-targeted rapid-acting insulin formulation for type 1 diabetes, is noninferior to insulin lispro for improvement of HbA1c and is associated with a lower hypoglycemia risk in some patients.

Measuring succinate levels before bariatric surgery may serve as a predictive marker for remission of type 2 diabetes.